MTHFR and Pregnancy: What the Evidence Actually Shows

This article is for educational purposes only. It is not medical advice and does not replace prenatal care. Do not change your supplementation or medication regimen during pregnancy without consulting your obstetrician or midwife.

If you are pregnant or planning a pregnancy and have learned you carry an MTHFR gene variant, you are not alone in feeling concerned. MTHFR is one of the most searched genetic topics among expectant parents — and one of the most polarizing in clinical medicine.

This page reviews what the published evidence actually shows about MTHFR and pregnancy outcomes, what major health organizations recommend, and where the science remains uncertain.

What Is MTHFR?

MTHFR (methylenetetrahydrofolate reductase) is a gene that encodes an enzyme involved in folate metabolism. The MTHFR enzyme converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (L-methylfolate), the biologically active form of folate used in methylation reactions throughout the body.

Two common variants are widely studied:

• C677T (rs1801133): The most studied variant. People homozygous (TT) for C677T have approximately 30% of normal MTHFR enzyme activity. Heterozygotes (CT) have approximately 65% activity.
• A1298C (rs1801131): Less well-characterized. Homozygous (CC) individuals show modestly reduced enzyme activity, but the clinical significance is less established than C677T.

For a deeper dive into C677T management, see our MTHFR C677T guide.

What Research Shows About Folate Metabolism

Folate is essential during pregnancy for DNA synthesis, cell division, and neural tube closure in the developing embryo. The neural tube closes within the first 28 days after conception — often before a pregnancy is recognized.

The MTHFR enzyme converts dietary folate (and supplemental folic acid) into L-methylfolate. Reduced enzyme activity means this conversion happens more slowly. In individuals homozygous for C677T (TT genotype), this can lead to:

• Lower circulating L-methylfolate levels
• Higher homocysteine levels (hyperhomocysteinemia)
• Potentially reduced methylation capacity

However, reduced enzyme activity does not mean zero activity. Even TT homozygotes retain approximately 30% of normal enzyme function, and adequate folate intake can compensate for reduced conversion efficiency in most cases.

Neural Tube Defects: The Evidence

The association between MTHFR C677T and neural tube defects (NTDs) is the most studied aspect of MTHFR and pregnancy. Key findings from large studies:

• A 2005 Cochrane review confirmed that periconceptional folic acid supplementation reduces NTD risk by approximately 70%, regardless of MTHFR genotype.
• Population-level folic acid food fortification programs (mandatory in the US since 1998, per CDC) have reduced NTD rates across all MTHFR genotypes.
• Meta-analyses show that maternal C677T TT genotype is associated with a modestly increased NTD risk (pooled OR approximately 1.8–2.0) compared to CC genotype — but this risk is largely mitigated by adequate folate status.
• The absolute risk of NTDs in the general population is low (approximately 1 in 1,000 pregnancies in countries with fortification), and most C677T TT carriers have unaffected pregnancies.

The evidence consistently shows that folate intake — not MTHFR genotype — is the primary modifiable factor for NTD prevention.

What Major Health Bodies Recommend

Major medical organizations have issued clear guidance on folate supplementation during pregnancy:

• CDC: Recommends 400 mcg of folic acid daily for all women of reproductive age, starting at least one month before conception and continuing through early pregnancy.
• ACOG (American College of Obstetricians and Gynecologists): Recommends 400–800 mcg of folic acid daily for most women; 4 mg daily for women with a prior NTD-affected pregnancy.
• WHO: Recommends 400 mcg folic acid daily from pre-conception through the first 12 weeks of pregnancy.

Notably, none of these organizations recommend routine MTHFR testing or different supplementation protocols based on MTHFR status. The AAFP has specifically recommended against routine MTHFR testing in clinical practice.

What Is Not Proven

Several claims about MTHFR and pregnancy circulate widely but are not well-supported by current evidence:

• MTHFR causes recurrent pregnancy loss: Some observational studies have reported associations between C677T and recurrent miscarriage, but systematic reviews have not found consistent evidence. ACOG does not recommend MTHFR testing as part of recurrent pregnancy loss workups.
• Methylfolate is required instead of folic acid: While L-methylfolate bypasses the MTHFR enzyme, there is no large-scale trial evidence that methylfolate is superior to folic acid for NTD prevention in any MTHFR genotype. The landmark trials demonstrating NTD prevention used folic acid. Some practitioners prefer methylfolate for C677T TT individuals, but this is based on biochemical reasoning rather than pregnancy outcome data.
• MTHFR-specific supplementation protocols are necessary: High-dose methylfolate, methyl-B12, and "methylation support" stacks marketed to MTHFR carriers during pregnancy lack clinical trial evidence for improved outcomes.

For information on supplements discussed in the MTHFR community, see our MTHFR supplements evidence review and supplements to watch for. For a broader overview of testing methylation pathways — including blood biomarkers and genetic panels — see our methylation testing guide.

Safety and Clinician Guidance

If you have learned about your MTHFR status and are pregnant or planning a pregnancy:

• Do not stop folic acid unless specifically directed by your healthcare provider. Folic acid is safe and effective for MTHFR carriers in the general population.
• Discuss your results with your OB or midwife. They can evaluate your folate status in context of your full clinical picture, including diet, other risk factors, and family history.
• Be cautious with online protocols. Supplement recommendations from non-medical sources may not account for individual circumstances, drug interactions, or dosing safety during pregnancy.
• Consider the source. Many websites discussing MTHFR and pregnancy sell supplements. Look for references to peer-reviewed studies and major guideline organizations.

For context on the limitations of genetic testing generally, see our limitations page. For background on how genetic testing relates to health decisions, see our introductory guide.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for prenatal care. Always consult your obstetrician, midwife, or qualified healthcare provider before making changes to supplementation or medication during pregnancy.